Si Bone Inc (NASDAQ:), a medical device company, has seen its stock price touch a 52-week low, dipping to $11.75. This latest price level reflects a significant downturn from the previous year, with the stock experiencing a 1-year change of -33.41%. Investors are closely monitoring Si Bone’s performance as the company navigates through a challenging market environment, which has seen many stocks retract from their previous highs. The 52-week low serves as a critical point of interest for both current shareholders and potential investors, as they assess the company’s valuation and future prospects in the dynamic healthcare sector.
In other recent news, SI-BONE Inc. announced a significant 19% increase in worldwide revenue to $40.3 million in its Q3 earnings. This growth was largely attributed to an 18% rise in U.S. sales, contributing $38.3 million, and a 21% hike in international sales, totaling $2.1 million. The medical device company’s gross profit was $31.9 million, with a gross margin of 79%, and it reported a loss of $200,000, nearing its adjusted EBITDA breakeven point, marking a substantial 94% improvement from the previous year.
Further developments include SI-BONE’s receipt of 510(k) clearance for its iFuse-TORQ TNT device. The company also revised its 2024 revenue guidance to $165-$166 million, projecting a growth rate of 19%-20%, and anticipates reaching adjusted EBITDA profitability in the fourth quarter of 2024. Despite some disruptions due to Hurricane Helene and a 4% increase in operating expenses, the company maintains a positive outlook for 2025, planning to expand its sales force and leverage favorable reimbursement conditions.
On the analyst front, Needham reiterated its Buy rating on SI-BONE, maintaining that the company’s higher-end Medicare Open Payments are reasonable and do not raise concerns. The firm’s analysis, which considered 50 previous and ongoing investigations in the medical technology sector, underscored SI-BONE’s strong financial position. Needham suggests that the recent dip in share price presents a buying opportunity, emphasizing the company’s robust financial health as a key factor for maintaining the Buy rating.
InvestingPro Insights
Si Bone Inc’s recent touch of a 52-week low aligns with InvestingPro data, which confirms the stock is trading near its 52-week low. This price movement has resulted in a year-to-date total return of -42.12%, underscoring the challenges faced by the company. Despite the downturn, Si Bone’s financial health shows some positive signs. An InvestingPro Tip highlights that the company holds more cash than debt on its balance sheet, which could provide financial flexibility during this period of stock price weakness.
Additionally, Si Bone’s revenue growth remains strong, with an 18.98% increase over the last twelve months, reaching $157.03 million. This growth trajectory is supported by another InvestingPro Tip indicating that six analysts have revised their earnings upwards for the upcoming period, suggesting potential optimism about the company’s near-term performance.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights that could be valuable in assessing Si Bone’s future prospects amidst its current stock price challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
